|
个人基本信息
性别：保密 生日：1974-02-19
所在城市： QQ：
联系MSN：
注册日期：2017-05-26 02:19:11
自我介绍：SHERIDAN, Ill. (AP) - U.S. prisons are experimenting with a high-priced monthly injection that could help addicted inmates stay off opioids after they are released, but skeptics question its effectiveness and say the manufacturer has aggressively marketed an unproven drug to corrections officials. A single shot of <a href="http://avtonachalo.ru/index.php?subaction=userinfo&user=ohovixo">avtonachalo.ru</a> Vivitrol, given in the buttocks, lasts for four weeks and eliminates the need for the daily doses common with alternatives such as methadone. But each shot costs as much <a href="http://www.fireflies.co.il/index.php?option=com_easybookreloaded">fireflies.co.il</a> as $1,000, and because the drug has a limited track record, experts do not agree on how well it works.<br /><br />Proponents say Vivitrol could save money compared with the cost of locking up a drug offender - about $25,000 a year for each inmate at the Sheridan Correctional Center, 70 miles southwest of Chicago. In this Oct. 17, 2016 photo, inmate Joshua Meador speaks <a href="http://kisspiss.com/index.php?subaction=userinfo&user=yxelak">strona www</a> about addiction at Sheridan Correctional Center in Sheridan, Ill. Meador, a recovering heroin addict, hopes to get into a Vivitrol program at Sheridan before his release in January.<br /><br />U.S. prisons are experimenting with <a href="http://www.dancor.sumy.ua/blogs/entries/198457">tu</a> the high-priced monthly injection that could help addicted inmates stay off opioids after they are released. (AP Photo/Kamil Krzaczynski) Dr. Joshua Lee, of New York University's medical school, said more evidence is needed to determine whether the medication can help substantial numbers of people and whether it's worth paying for, but the early <a href="http://www.janeausten.pl/modules.php?name=Your_Account&op=userinfo&username=ugodopepo">www.janeausten.pl</a> results are encouraging. "It sounds good, and for some of us, it feels like the right thing to do," said Lee, a leading researcher on the <a href="http://www.oraportal.hu/hu/forum/user/3001-elirevy.html">oraportal.hu</a> treatment.
|
个人动态信息
最后登录时间：2017-05-26 02:19:12
最后登录IP所在地：欧洲和中东地区
主页被访问数：491
主页最近被访问日期：2024-05-16 13:10
|
